Bristol Myers Squibb Co/ US1101221083 /
2024-03-28 9:10:00 PM | Chg. +0.98 | Volume | Bid1:00:00 AM | Ask1:00:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
54.23USD | +1.84% | 14.35 mill. Turnover: 587.58 mill. |
54.00Bid Size: 200 | 54.72Ask Size: 100 | 109.66 bill.USD | 4.26% | 13.98 |
GlobeNewswire
03-28
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire
03-26
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates...
GlobeNewswire
03-26
Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Cl...
GlobeNewswire
03-23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...
GlobeNewswire
03-21
Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nou...
GlobeNewswire
03-20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
03-18
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Col...
GlobeNewswire
03-18
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Eva...
GlobeNewswire
03-15
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...
GlobeNewswire
03-14
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
GlobeNewswire
03-14
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
GlobeNewswire
03-11
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to ...
GlobeNewswire
03-11
Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitratio...
GlobeNewswire
03-05
Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound...
GlobeNewswire
03-04
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024